← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Biomedica Management Corporation
New York, NY
$4,303,668
Total funding
6
Grants
Funding over time
peak $1M · FY2005–15$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,303,668 · 6
By mechanism
R44$3,865,706 · 2
R43$437,962 · 4
Investigators at Biomedica Management Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Clinical Development of Hemostatic Agent ClotFoam for Severe Hemorrhage$1,012,644
R44 · FY2013 · HL
Clinical Development of Hemostatic Agent ClotFoam for Severe Hemorrhage$965,052
R44 · FY2012 · HL
Intracavitary Hemostatic Agent for Non-compressible Hemorrhage$619,743
R44 · FY2009 · HL
Intracavitary Hemostatic Agent for Non-compressible Hemorrhage$381,263
R44 · FY2010 · HL
Anti-Selectin Blocker for Liver Ischemic Injury$359,522
R44 · FY2004 · DK
Anti-Selectin Blocker for Liver Ischemic Injury$359,522
R44 · FY2005 · DK
Anti-Selectin Blocker for Organ Ischemic Injury$107,000
R43 · FY2002 · DK
Anti-ischemic Resuscitation Fluid$104,178
R43 · FY2007 · GM
Intracavitary Hemostatic Agent for Non-compressible Hemorrhage$103,148
R43 · FY2007 · HL
Immunomodulation of Sophorolipids in Sepsis$99,999
R43 · FY2008 · AI
Intracavitary Hemostatic Agent for Non-compressible Hemorrhage$93,680
R44 · FY2010 · HL
Anti-Selectin Blocker for Liver Ischemic Injury$69,280
R44 · FY2006 · DK
Anti-ischemic Resuscitation Fluid$23,637
R43 · FY2008 · GM
Clinical Development of Non-compressible Hemostatic Agent for High-Volume Hemorrhage$5,000
R44 · FY2015 · HL